Skip to content

Toxins and Delivery in e-Cigarette Users

Electronic Cigarettes: Potential Toxicant (Acrolein) and Nicotine Delivery in Users

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01714778
Acronym
TADEUS
Enrollment
40
Registered
2012-10-26
Start date
2013-02-28
Completion date
2014-01-31
Last updated
2014-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Smoking Cessation

Brief summary

Electronic cigarettes or e-cigarettes (EC) may have a potential public health benefit as a safer alternative to smoking and possibly also as an aid in tobacco dependence treatment. However, there are concerns about their safety and whether they can deliver nicotine consistently and in doses necessary for such effects. To be able to consider the safety of ECs and their potential in harm reduction, data are needed comparing the exposure to the potential toxicant, acrolein, in smokers of conventional cigarettes, users of EC, and people who use both products at the same time. To accurately assess EC nicotine delivery, data are needed from people who use them regularly, as there is some evidence of higher and faster nicotine absorption in experienced users compared with naïve users who try them once in an artificial laboratory setting. This study will provide information on both of these issues. Forty smokers will be given EC to use, in addition to behavioural support, as part of a stop smoking attempt. Levels of acrolein and nicotine will be measured before and after 4 weeks of EC use.

Interventions

OTHERe-Cigarette

Sponsors

Queen Mary University of London
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Smokers who want help in quitting * Aged 18 or over

Exclusion criteria

* Women who are pregnant or breastfeeding * People with any current serious illness

Design outcomes

Primary

MeasureTime frameDescription
Change in urinary 3HPMA levels after 4 weeks use of electronic cigarettes.4 weeksChange in urinary 3HPMA levels (a metabolite of acrolein) after 4 weeks use of electronic cigarettes, in both individuals who have stopped smoking conventional cigarettes and those who are still using them.

Secondary

MeasureTime frameDescription
Change in nicotine levels after 4 weeks use of electronic cigarettes (EC)4 weeksChange in blood nicotine levels obtained from using an EC after 4 weeks use of electronic cigarettes (10 participants only).
Electronic cigarette acceptability6 monthsParticipants' views on electronic cigarettes
Use of electronic cigarettes6 monthsParticipants' use of electronic cigarettes

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 22, 2026